Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03110458 · ClinicalTrials.gov registry record · Phase 2
Efficacy of SENS-111 in Patients Suffering From Acute Unilateral Vestibulopathy
A Phase 2 study, sponsored by Sensorion.
- Completed
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
NCT03110458 is a Phase 2 study that has completed, run by Sensorion. The registered enrollment target is 107 participants.
The verdict
NCT03110458, a Phase 2 study, has completed, sponsored by Sensorion.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
Study Summary
A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 2 dose-regimens of orally administered SENS-111 (100mg and 200mg) given during 4 days in patients suffering from Acute Unilateral Vestibulopathy (AUV)
Interventions
- DRUG Placebo Oral Tablet
- DRUG SENS-111 100mg
- DRUG SENS-111 200mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2017-08-16 |
| Est. Completion | 2019-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03110458
The ClinicalTrials.gov registry entry for NCT03110458 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sensorion, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo Oral Tablet is the first listed.
NCT03110458 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03110458 about?
NCT03110458 is a clinical study titled "Efficacy of SENS-111 in Patients Suffering From Acute Unilateral Vestibulopathy". A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 2 dose-regimens of orally administered SENS-111 (100mg and 200mg) given during 4 days in patients suffering from Acute Unilateral Vestibulopathy (AUV)
What is the current status of trial NCT03110458?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2017-08-16. Estimated completion is 2019-10-15.
What interventions are being tested in trial NCT03110458?
The interventions under investigation include: Placebo Oral Tablet (DRUG), SENS-111 100mg (DRUG), SENS-111 200mg (DRUG).
Who is sponsoring clinical trial NCT03110458?
This trial is sponsored by Sensorion, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.